Antitumor effect of combination of hyperthermotherapy and 5-aminolevulinic acid (ALA)

Anticancer Research

Volumn 33, Issue 7, 2013, Pages 2861-2866

  Takahashi, Kiwamu ^a   Hasegawa, Takeo ^b,c   Ishii, Takuya ^a   Suzuki, Atsuko ^a   Nakajima, Motowo ^a   Uno, Kazuko ^b   Yasuda, Iuko ^b   Kishi, Atsuko ^b   Sadamoto, Kaori ^b   Abe, Fuminori ^a   Tanaka, Tohru ^a  

^a SBI Pharmaceuticals Co   (Japan)

^b Louis Pasteur Center for Medical Research   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

5 Aminolevulinic acid; ALA; Animal tumor model; Hyperthermia; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER GRAFT; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CONFERENCE PAPER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HYPERTHERMIC THERAPY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

5-AMINOLEVULINIC ACID; ALA; ANIMAL TUMOR MODEL; HYPERTHERMIA; PROTOPORPHYRIN IX;

AMINOLEVULINIC ACID; ANIMALS; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; FEMALE; HYPERTHERMIA, INDUCED; LIGHT; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS;

EID: 84883277398     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Bergs JW, Haveman J, Ten Cate R, Medema JP, Franken NA and Van Bree C: Effect of 41°C and 43°C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin. Oncol Rep 18: 219-226, 2007.
2. Hildebrandt B and Wust P: Interactions between hyperthermia and cytotoxic drugs. Cancer Treat Res 134: 185-193, 2007.
3. Franke K, Kettering M, Lange K, Kaiser WA and Hilger I: The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels. Int J Nanomedi 8: 351-363, 2013.
4. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43: 33-56, 2002.
5. Issels RD: Hyperthermia adds to chemotherapy. Eur J Cancer 44: 2546-2554, 2008.
6. Katschinski DM: On heat and cells and proteins. News Physiol Sci 19: 11-15, 2004.
7. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL and Hart AA: Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355: 1119-1125, 2000.
8. Ishizuka M, Abe F, Sano Y, Takahashi K, Inoue K, Nakajima M, Kohda T, Komatsu N, Ogura S and Tanaka T: Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 11: 358-365, 2011.
9. Berlin NI, Neuberger A and Scott JJ: The metabolism of delta - aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N. Biochem J 64: 80-90, 1956.
10. Berlin NI, Neuberger A and Scott JJ: The metabolism of deltaaminolaevulic acid. 2. Normal pathways, studied with the aid of 14C. Biochem J 64: 90-100, 1956.
11. Khan AA and Quigley JG: Control of intracellular heme levels: Heme transporters and heme oxygenases. Biochim Biophys Acta 1813: 668-682, 2011.
12. Frolund S, Marquez OC, Larsen M, Brodin B and Nielsen CU: Deltaaminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol 159: 1339-1353, 2010.
13. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F and Reulen H-J: Fluorescence-guided surgery with 5- aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. The Lancet Oncology 7: 392-401, 2006.
14. Inoue K, Fukuhara H, Shimamoto T, Kamada M, Iiyama T, Miyamura M, Kurabayashi A, Furihata M, Tanimura M, Watanabe H and Shuin T: Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 118: 1062-1074, 2012.
15. Grant WE, Hopper C, MacRobert AJ, Speight PM and Bown SG: Photodynamic therapy of oral cancer: Photosensitisation with systemic aminolaevulinic acid. Lancet 342: 147-148, 1993.
16. Kishi K, Fujiwara Y, Yano M, Inoue M, Miyashiro I, Motoori M, Shingai T, Gotoh K, Takahashi H, Noura S, Yamada T, Ohue M, Ohigashi H and Ishikawa O: Staging laparoscopy using ALAmediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer. J Surg Oncol 106: 294-298, 2012.
17. Murayama Y, Ichikawa D, Koizumi N, Komatsu S, Shiozaki A, Kuriu Y, Ikoma H, Kubota T, Nakanishi M, Harada Y, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Takamatsu T and Otsuji E: Staging fluorescence laparoscopy for gastric cancer by using 5- aminolevulinic acid. Anticancer Res 32: 5421-5427, 2012.
18. Talmadge E, Lenz BF, Collins MS, Uithoven KA, Schneider MA, Adams JS, Pearson JW, Agee WJ, Fox RE and Oldham RK: Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Inst Mitt 74: 219-29, 1984.
19. Freireich EJ, Gehan EA, Rall DP, Schmidt LH and Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244, 1966
20. Ishizuka M, Hagiya Y, Mizokami Y, Honda K, Tabata K, Kamachi T, Takahashi K, Abe F, Tanaka T, Nakajima M, Ogura S and Okura I: Porphyrins in urine after administration of 5- aminolevulinic acid as a potential tumor marker. Photodiagnosis Photodyn Ther 8: 328-331, 2011.
21. Yamamoto J, Ogura S, Tanaka T, Kitagawa T, Nakano Y, Saito T, Takahashi M, Akiba D and Nishizawa S: Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells in vitro. Oncol Rep 27: 1748-1752, 2012.
22. Nonaka M, Yamamoto M, Yoshino S, Umemura S, Sasaki K and Fukushima T: Sonodynamic therapy consisting of focused ultrasound and a photosensitizer causes a selective antitumor effect in a rat intracranial glioma model. Anticancer Res 29: 943-950, 2009.
23. Yamaguchi F, Asakura T, Takahashi H, Kitamura T and Teramoto A: Low frequency ultrasonication induced antitumor effect in 5-aminolevulinic acid treated malignant glioma. J Cancer Thera 4: 170-175, 2013.
24. Ohmura T, Fukushima T, Shibaguchi H, Yoshizawa S, Inoue T, Kuroki M, Sasaki K and Umemura S: Sonodynamic therapy with 5-aminolevulinic acid and focused ultrasound for deep-seated intracranial glioma in rat. Anticancer Res 31: 2527-2533, 2011.
25. Chibazakura T, Toriyabe Y, Takahashi K, Kawakami M, Ogura S, Abe F, Nakajima M and Tanaka T: Enhancement of hyperthermia-induced tumor cell death by 5-aminolevulinic acid. In: The 11th International Congress of Hyperthemic Oncology (Proceeding). Kyoto, 2012.
26. Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L, Moretta A and Ferlazzo G: Dendritic cell editing by activated natural killer cells results in a more protective cancerspecific immune response. PLoS One 7: e39170, 2012.
27. Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O and Tsukamoto K: Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: Role of asialo GM1- positive cells. Immunology 60: 173-179, 1987.
28. Skivka LM, Gorobets OB, Kutsenok VV, Lozinsky MO, Borisevich AN, Fedorchuk AG, Kholin VV and Gamaleya NF: 5-Aminolevulinic acid mediated photodynamic therapy of Lewis lung carcinoma: A role of tumor infiltration with different cells of immune system. Exp Oncol 26: 312-315, 2004.
29. Moretta A, Marcenaro E, Parolini S, Ferlazzo G and Moretta L: NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15: 226-233, 2008.